SCHEMBL669226

SCHEMBL669226

O=COCc1ccc2c(c1)OCO2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.59
TDP1 Q9NUW8 2/20 0.58
KMT2A Q03164 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
CYP1A2 P05177 2/20 0.53
MAPT P10636 1/20 0.53
TAAR1 Q96RJ0 3/20 0.50
CMA1 P23946 1/20 0.50
ALDH1A1 P00352 2/20 0.49
CYP2C19 P33261 1/20 0.49
SLC6A4 P31645 2/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
CALM1 P0DP23 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27901932 0.83 TAAR1 (0.56) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL12342025 0.83 CYP3A4 (0.62) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL27474367 0.81 TAAR1 (0.53) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL14829844 0.80 CYP3A4 (0.52) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL11240060 0.80 CYP3A4 (0.64) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL30194840 0.80 CYP3A4 (0.64) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL3417124 0.80 CYP3A4 (0.64) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL406700 0.78 CYP3A4 (0.70) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL9548239 0.78 CYP3A4 (0.62) CYP3A4TDP1KMT2AL3MBTL1CYP1A2
SCHEMBL30194501 0.78 CYP3A4 (0.70) CYP3A4TDP1KMT2AL3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114989131-B N' - (2- (benzo [1,3] dioxolan-5-yl) acyl) aryl hydrazide compound as well as synthesis and application thereof 云南大学 2023-10-24 CN claimed
CN-116444477-A Preparation method and application of bromopiperonyl carboxylic acid 宁波九胜创新医药科技有限公司 2023-07-18 CN claimed
CN-114989131-A N' - (2- (benzo [1,3] dioxolane-5-yl) acyl) aroyl hydrazide compound and synthesis and application thereof 云南大学 2022-09-02 CN claimed
EP-1501812-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-12-30 EP claimed
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP claimed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US claimed
US-7179896-B2 Method of making PNA oligomers PANAGENE, INC. (KR) 2007-02-20 US claimed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP claimed
EP-1501812-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-05-24 EP claimed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP claimed
US-20060003374-A1 Method of making PNA oligomers KIM SUNG K 2006-01-05 US claimed
US-6969766-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-29 US claimed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO claimed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US claimed
EP-1501812-A1 PNA MONOMER AND PRECURSOR Panagene, Inc. (KR) 2005-02-02 EP claimed
US-20030225252-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-12-04 US claimed
WO-2003091231-A1 PNA MONOMER AND PRECURSOR PANAGENE, INC. (US) 2003-11-06 WO claimed
CN-118530209-A Piperine derivative with antitumor activity and preparation method, pharmaceutical composition and application thereof 江苏海洋大学 2024-08-23 CN disclosed
US-4933355-A ALDOSE REDUCTASE INHIBITORS SANKYO COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225252-A1 PNA monomer and precursor PNISR, RNGTT, NCL CYP3A4 4571/4885TDP1 628/4885KMT2A 4071/4885
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 CYP3A4 4099/4885TDP1 1522/4885KMT2A 4464/4885
US-20060003374-A1 Method of making PNA oligomers RNGTT, POLL, PNISR CYP3A4 4675/4885TDP1 711/4885KMT2A 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.